Lee SH, Park W, Lee SW, et al. - In this study, the frequency of peripheral disease and the effectiveness of adalimumab were tested among Korean patients with ankylosing spondylitis (AS). Researchers assessed peripheral disease in consecutively enrolled patients with active AS (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] score ≥ 4). Researchers subsequently included an adult subpopulation in a prospective, observational study and received adalimumab 40 mg, every 2 weeks. They evaluated AS disease activity by BASDAI score, and effectiveness in peripheral disease assessed via changes in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES; 0‐13), swollen joint and tender joint counts (SJC, 0‐44; TJC, 0‐46), and dactylitic digits from baseline, during a 52‐week follow‐up. This study included a total of 1,161 Korean patients with AS. This study's findings demonstrate that of these Korean individuals with AS, those who received adalimumab indicated higher prevalence for peripheral symptoms and, subsequently, adalimumab treatment improved peripheral features of their AS.